PWRM, Power 3 Medical Products Inc, PWRM.OB

DrStockPick.com News Report!

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Appoints Medical Director

-Lourdes R. Bosquez, MD, PA Appointed New Medical Director for PWRM-

 

Friday August 28, 2009

************************************************************** Power3 Medical Products, Inc. Appoints Medical Director

Lourdes R. Bosquez, MD, PA Appointed New Medical Director for Power3 Medical Products, Inc.

Woodlands, TX, - (CRWENEWSWIRE ) Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced that Lourdes R. Bosquez, MD, PA, was appointed Medical Director of the Company.

Power3 Medical Products, Inc., a biotechnology company with diagnostic products for Alzheimer’s disease, Parkinson’s disease, Breast Cancer and other diseases, has secured the

...

PWRM, Power 3 Medical Products Inc, PWRM.OB

DrStockPick.com News Report!

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Appoints Medical Director

-Lourdes R. Bosquez, MD, PA Appointed New Medical Director for PWRM-

 

Thursday August 27, 2009

************************************************************** Power3 Medical Products, Inc. Appoints Medical Director

Lourdes R. Bosquez, MD, PA Appointed New Medical Director for Power3 Medical Products, Inc.

Woodlands, TX, - (CRWENEWSWIRE ) Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced that Lourdes R. Bosquez, MD, PA, was appointed Medical Director of the Company.

Power3 Medical Products, Inc., a biotechnology company with diagnostic products for Alzheimer’s disease, Parkinson’s disease, Breast Cancer and other diseases, has secured the

...

Las Vegas CRWENewswire.com is pleased to announce a stock highlight on Dana Resources (OTC.BB:DANR), Power3 Medical Products, Inc. (OTCBB:PWRM), NewMarket Technology, Inc. (Pinksheets:NWMT)

Dana Resources (OTC.BB:DANR), a US-based precious metals exploration and development company, is pleased to announce the initiation of the production program at its Collota gold deposit. Dana Resources currently owns and operates seven mining projects located in Peru’s most prolific mining regions.

About Dana Resources Dana Resources is a precious and base metals exploration company with offices in the United States and Peru. Dana’s management team possesses local knowledge, extensive international connections, a wealth of experience and technical expertise in mining, mining finance, exploration and production. Dana Resources has acquired a portfolio of gold, silver and other precious & base metal properties located in Peru’s most prolific mining regions. With Peru growing as a producer of gold, silver and other metals on the international market, Dana Resources is well

...

PWRM, Power 3 Medical Products Inc, PWRM.OB

DrStockPick.com News Report!

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Appoints Medical Director

-Lourdes R. Bosquez, MD, PA Appointed New Medical Director for PWRM-

 

Wednesday August 26, 2009

************************************************************** Power3 Medical Products, Inc. Appoints Medical Director

Lourdes R. Bosquez, MD, PA Appointed New Medical Director for Power3 Medical Products, Inc.

Woodlands, TX, - (CRWENEWSWIRE - 08/26/09) Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), today announced that Lourdes R. Bosquez, MD, PA, was appointed Medical Director of the Company.

Power3 Medical Products, Inc., a biotechnology company with diagnostic products for Alzheimer’s disease, Parkinson’s disease, Breast Cancer and other diseases,

...

We are pleased with UK-based Shire Plc’s (SHPGY) research collaboration with Denmark’s Santaris Pharma for the development of new drugs for rare diseases. Shire will make an upfront payment of $6.5 million and an additional $13.5 million on completion of certain initial studies.

Santaris Pharma also has the potential to get another $72 million in the form of development, regulatory and sales-related milestone payments for each of its five pipeline candidates along with royalties on sales once these products are commercialized. The initial term of the collaboration is two years and Shire may extend it by another two-year term.

With this deal, Shire will be able to utilize Santaris' proprietary locked nucleic acid (LNA) technology platform to develop treatments for several life threatening conditions that cannot be cured by enzyme replacement therapy (ERT), a platform where Shire has a strong presence. We believe the alliance will be beneficial

...

DrStockPick.com Stock Report!

Tuesday August 18, 2009

**************************************************************

Desert Equity LP, a Delaware limited partnership, today announced that it has commenced its previously announced cash tender offer for up to a total of 3,740,000 shares of common stock, or approximately 16.3% of the shares outstanding, of White Electronic Designs Corporation (Nasdaq: WEDC), at a price of $4.25 net per share in cash (subject to applicable withholding of U.S. federal, state and local taxes).

Novavax, Inc. (Nasdaq: NVAX) announced positive preclinical results with Novavax’s 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. The study, conducted by scientists from Novavax and the Centers for Disease Control and Prevention (CDC) based in Atlanta, GA, under

...

We are pleased with AstraZeneca’s (AZN) decision (on July 8) to go ahead with the development of AZD1446 for the treatment of Alzheimer's disease (AD). This drug, currently in phase I, was discovered in collaboration with Targacept.

The company also decided to conduct additional trials of AZD3480 (another drug for neuroscience) by initiating phase IIb studies in attention deficit/hyperactivity disorder (ADHD). Last year, the evaluation of AZD3480 for the treatment of AD and Schizophrenia had been inconclusive.

But in May 2009, preliminary result of AZD3480 showed significant improvement in symptoms of ADHD. With the progress of this drug candidate, AstraZeneca has agreed to make a milestone payment of $10 million to its collaborating partner Targacept.

Many pharma players have been eyeing this segment as AD had been the third-leading cause of death in the recent past. More than 24 million people are already affected worldwide and the number

...

While the loss of exclusivity of Shire's (SHPGY) Adderall XR will result in revenue falling in 2009 relative to 2008, we believe Vyvanse will be able to continue to post strong sales growth due to its strong differentiating characteristics.We believe the drug is much more than just an Adderall XR substitute, which should allow continued share gains despite significant generic competition. The adult indication should provide an additional catalyst to growth.The recent launch of Mezavant in Europe and Canada and the continued ramp of Fosrenol in Europe should make a healthy positive impact on the top-line going forward. Eleprase should ramp very quickly with the recent approvals in Canada, Europe, Japan, Mexico, Russia and Brazil, and should be a big contributor to sales growth.Lialda uptake has been very impressive and we expect additional market share penetration, despite Takeda no longer ...

Vyvanse and New Products Drive ShireWhile the loss of exclusivity of Adderall XR will result in revenue falling in 2009 relative to 2008 for Shire Plc (SHPGY), we believe Vyvanse will be able to continue to post strong sales growth due to its strong differentiating characteristics. We believe the drug is much more than just an Adderall XR substitute, which should allow continued share gains despite significantly more generic competition. The adult indication should provide an additional catalyst to growth.The recent launch of Mezavant in Europe and Canada and the continued ramp of Fosrenol in Europe should make significant positive impacts on the top-line going forward. Eleprase should ramp very quickly with the recent approvals in Canada, Europe, Japan, Mexico, Russia and Brazil, and should be a big contributor to sales growth. Lialda uptake has been very impressive and we expect additional market share ...

Noven Pharmaceuticals, Inc. (...